MD PhD FEBU FACS
Rush University, Chicago, IL
Dr. Riccardo Autorino is a fellowship-trained, board-certified urologist, who specializes in minimally invasive and robotic surgery for kidney, prostate, and upper tract urothelial cancers, with a particular focus on single-port robotic techniques. He serves as the Director of Clinical Outcomes Research, Director of the International Research Fellowship Program, and Associate Director of the RSMIUO fellowship at the Glickman Urological Institute. Dr. Autorino earned his medical degree from the Federico II University and a PhD in Endocrinological, Andrological, and Urological Sciences from Vanvitelli University in Naples, Italy. He completed both research and clinical fellowships in Advanced Laparoscopy and Robotics at Cleveland Clinic. He also graduated from the Surgical Leadership Program, Harvard Medical School (Cambridge, MA). Before returning to Cleveland, he served as Director of Urologic Oncology at Virginia Commonwealth University (Richmond, VA) and as Director of Surgical Innovation and Clinical Research at Rush University Medical Center (Chicago, IL). An internationally recognized academic leader, Dr. Autorino has authored more than 700 peer-reviewed publications and serves on the editorial boards of multiple leading journals, including European Urology, World Journal of Urology, Minerva Urology, Urology Video Journal. He has a 91 Google scholar h index and 73 Scopus h index. He leads and contributes to several multicenter research collaborations, including the ROBUUST study on robotic surgery for upper tract urothelial cancer and the SPARC program on single-port robotic surgery. Dr. Autorino’s work has been recognized with numerous national and international awards for teaching, research, and innovation. He is regularly invited as faculty at major international conferences. He is actively involved in mentoring residents and fellows and continues to advance minimally invasive techniques to improve outcomes for patients with urologic cancers.
Disclosure information not submitted.
Monday, May 1, 2023
9:30 AM – 11:30 AM CST